PMID- 33649917
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210731
IS  - 1432-2323 (Electronic)
IS  - 0364-2313 (Print)
IS  - 0364-2313 (Linking)
VI  - 45
IP  - 6
DP  - 2021 Jun
TI  - Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple 
      Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie 
      Endocrinienne) and GTE (Groupe d'etude des Tumeurs Endocrines) Study.
PG  - 1794-1802
LID - 10.1007/s00268-021-06005-7 [doi]
AB  - AIM: To assess postoperative complications and control of hormone secretions 
      following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia 
      type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP-NETs). 
      BACKGROUND: The use of PD to treat MEN1 remains controversial, and evaluating the 
      right place of PD in MEN1 disease makes sense. METHODS: Thirty-one MEN1 patients 
      from the Groupe d'etude des Tumeurs Endocrines MEN1 cohort who underwent PD for 
      DP-NETs between 1971 and 2013 were included. Early and late postoperative 
      complications, secretory control and overall survival were analyzed. RESULTS: 
      Indication for surgery was: Zollinger-Ellison syndrome (n = 18; 58%), 
      nonfunctioning tumor (n = 9; 29%), insulinoma (n = 2; 7%), VIPoma (n = 1; 3%) and 
      glucagonoma (n = 1; 3%). Mean follow-up was 141 months (range 0-433). Pancreatic 
      fistulas occurred in 5 patients (16.1%), distant metastases in 6 (mean onset of 
      43 months; range 13-110 months), postoperative diabetes mellitus in 7 (22%), and 
      pancreatic exocrine insufficiency in 6 (19%). Five-year overall survival was 
      93.3% [CI 75.8-98.3] and ten-year overall survival was 89.1% [CI 69.6-96.4]. 
      After a mean follow-up of 151 months (range 0-433), the biochemical cure rate for 
      MEN-1 related gastrinomas was 61%. CONCLUSION: In MEN1 patients, 
      pancreatoduodenectomy can be used to control hormone secretions (gastrin, 
      glucagon, VIP) and to remove large NETs. PD was found to control gastrin 
      secretions in about 60% of cases.
FAU - Santucci, Nicolas
AU  - Santucci N
AD  - Department of Digestive and Endocrine Surgery, Dijon University Hospital, 
      University of Burgundy, Dijon, France. nicolas.santucci@chu-dijon.fr.
AD  - INSERM, U1231, EPICAD Team UMR "Lipids, Nutrition, Cancer", Dijon, France. 
      nicolas.santucci@chu-dijon.fr.
AD  - Service de Chirurgie Digestive, Cancerologique et Endocrinienne, CHU << Francois 
      Mitterrand >>, 14, rue Paul Gaffarel, 21079, Dijon Cedex, France. 
      nicolas.santucci@chu-dijon.fr.
FAU - Gaujoux, Sebastien
AU  - Gaujoux S
AD  - Department of Pancreatic and Endocrine Surgery, Cochin University Hospital, APHP, 
      Paris, France.
FAU - Binquet, Christine
AU  - Binquet C
AD  - INSERM, U1231, EPICAD Team UMR "Lipids, Nutrition, Cancer", Dijon, France.
AD  - INSERM, CIC1432, Clinical Epidemiology Unit, University of 
      Burgundy-Franche-Comte, Dijon, France.
FAU - Reichling, Cynthia
AU  - Reichling C
AD  - Department of Hepatogastroenterology and Digestive Oncology, Dijon University 
      Hospital, University of Burgundy, Dijon Cedex, France.
FAU - Lifante, Jean-Christophe
AU  - Lifante JC
AD  - Department of General, Digestive and Endocrine Surgery, University Hospital of 
      Lyon Sud and EA 7425 HESPER, Health Services and Performance Research, University 
      Claude-Bernard Lyon 1, Lyon, France.
FAU - Carnaille, Bruno
AU  - Carnaille B
AD  - Department of General and Endocrine Surgery, Lille University Hospital, Univ. 
      Lille, INSERM U1190, Lille, France.
FAU - Pattou, Francois
AU  - Pattou F
AD  - Department of General and Endocrine Surgery, Lille University Hospital, Univ. 
      Lille, INSERM U1190, Lille, France.
FAU - Mirallie, Eric
AU  - Mirallie E
AD  - Department of General and Endocrine Surgery, University Hospital of Nantes, 
      Nantes, France.
FAU - Facy, Olivier
AU  - Facy O
AD  - Department of Digestive and Endocrine Surgery, Dijon University Hospital, 
      University of Burgundy, Dijon, France.
FAU - Mathonnet, Muriel
AU  - Mathonnet M
AD  - Department of General, Digestive and Endocrine Surgery, Dupuytren University 
      Hospital, Limoges, France.
FAU - Goudet, Pierre
AU  - Goudet P
AD  - Department of Digestive and Endocrine Surgery, Dijon University Hospital, 
      University of Burgundy, Dijon, France.
AD  - INSERM, U1231, EPICAD Team UMR "Lipids, Nutrition, Cancer", Dijon, France.
LA  - eng
PT  - Journal Article
DEP - 20210301
PL  - United States
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
SB  - IM
MH  - Humans
MH  - *Insulinoma/surgery
MH  - *Multiple Endocrine Neoplasia Type 1/surgery
MH  - *Neuroendocrine Tumors/surgery
MH  - *Pancreatic Neoplasms/surgery
MH  - Pancreaticoduodenectomy
PMC - PMC8093175
EDAT- 2021/03/03 06:00
MHDA- 2021/07/09 06:00
PMCR- 2021/03/01
CRDT- 2021/03/02 06:22
PHST- 2021/01/30 00:00 [accepted]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2021/03/02 06:22 [entrez]
PHST- 2021/03/01 00:00 [pmc-release]
AID - 10.1007/s00268-021-06005-7 [pii]
AID - 6005 [pii]
AID - 10.1007/s00268-021-06005-7 [doi]
PST - ppublish
SO  - World J Surg. 2021 Jun;45(6):1794-1802. doi: 10.1007/s00268-021-06005-7. Epub 
      2021 Mar 1.